Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
0.9000
+0.0651 (7.80%)
May 16, 2025, 4:00 PM - Market closed
Cytosorbents Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 35.33 | 35.59 | 31.08 | 34.69 | 43.17 | 41 | Upgrade
|
| Revenue | 35.33 | 35.59 | 31.08 | 34.69 | 43.17 | 41 | Upgrade
|
| Revenue Growth (YoY) | -3.69% | 14.51% | -10.39% | -19.64% | 5.27% | 64.35% | Upgrade
|
| Cost of Revenue | 10.87 | 10.47 | 9.13 | 13.96 | 11.05 | 11.05 | Upgrade
|
| Gross Profit | 24.46 | 25.13 | 21.95 | 20.73 | 32.12 | 29.95 | Upgrade
|
| Selling, General & Admin | 34.14 | 35 | 38.31 | 36.5 | 38.48 | 31.51 | Upgrade
|
| Research & Development | 6.33 | 6.92 | 15.59 | 15.12 | 16.38 | 8.81 | Upgrade
|
| Operating Expenses | 40.48 | 41.91 | 53.9 | 51.62 | 54.86 | 40.32 | Upgrade
|
| Operating Income | -16.02 | -16.79 | -31.95 | -30.89 | -22.74 | -10.37 | Upgrade
|
| Interest Expense | -2 | -1.4 | -0.16 | - | - | -1.2 | Upgrade
|
| Interest & Investment Income | - | - | - | 0.13 | 0.03 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.21 | -4.22 | 1.95 | -2.45 | -2.58 | 2.61 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0 | 0.1 | -0.07 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -17.8 | -22.41 | -30.06 | -33.27 | -25.29 | -8.96 | Upgrade
|
| Asset Writedown | - | - | - | -0.64 | - | - | Upgrade
|
| Pretax Income | -17.8 | -22.41 | -30.06 | -33.91 | -25.29 | -8.96 | Upgrade
|
| Income Tax Expense | -1.69 | -1.69 | -0.81 | -1.09 | -0.74 | -1.13 | Upgrade
|
| Net Income | -16.11 | -20.72 | -29.25 | -32.81 | -24.56 | -7.84 | Upgrade
|
| Net Income to Common | -16.11 | -20.72 | -29.25 | -32.81 | -24.56 | -7.84 | Upgrade
|
| Shares Outstanding (Basic) | 56 | 54 | 45 | 44 | 43 | 39 | Upgrade
|
| Shares Outstanding (Diluted) | 56 | 54 | 45 | 44 | 43 | 39 | Upgrade
|
| Shares Change (YoY) | 18.40% | 21.90% | 2.49% | 0.49% | 11.70% | 20.35% | Upgrade
|
| EPS (Basic) | -0.29 | -0.38 | -0.65 | -0.75 | -0.57 | -0.20 | Upgrade
|
| EPS (Diluted) | -0.29 | -0.38 | -0.65 | -0.75 | -0.57 | -0.20 | Upgrade
|
| Free Cash Flow | -13.3 | -14.71 | -22.19 | -34.32 | -17.65 | -6.32 | Upgrade
|
| Free Cash Flow Per Share | -0.24 | -0.27 | -0.50 | -0.79 | -0.41 | -0.16 | Upgrade
|
| Gross Margin | 69.23% | 70.59% | 70.62% | 59.77% | 74.41% | 73.05% | Upgrade
|
| Operating Margin | -45.33% | -47.16% | -102.78% | -89.04% | -52.69% | -25.29% | Upgrade
|
| Profit Margin | -45.59% | -58.21% | -94.09% | -94.59% | -56.89% | -19.11% | Upgrade
|
| Free Cash Flow Margin | -37.66% | -41.33% | -71.39% | -98.94% | -40.88% | -15.42% | Upgrade
|
| EBITDA | -14.48 | -15.22 | -30.49 | -30 | -22.01 | -9.71 | Upgrade
|
| EBITDA Margin | -40.97% | -42.75% | -98.08% | -86.49% | -51.00% | -23.68% | Upgrade
|
| D&A For EBITDA | 1.54 | 1.57 | 1.46 | 0.88 | 0.73 | 0.66 | Upgrade
|
| EBIT | -16.02 | -16.79 | -31.95 | -30.89 | -22.74 | -10.37 | Upgrade
|
| EBIT Margin | -45.33% | -47.16% | -102.78% | -89.04% | -52.69% | -25.29% | Upgrade
|
| Revenue as Reported | - | - | - | 34.69 | 43.17 | 41 | Upgrade
|
| Advertising Expenses | - | - | - | 0.58 | 0.62 | 0.29 | Upgrade
|
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.